Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17.
By P. Goss, J. Ingle, S. Martino, N. Robert, H. Muss, M. Piccart, M. Castiglione, D. Tu, L. Shepherd, K. Pritchard and 8 more. Journal of the National Cancer Institute, 2005
1,077 citations recorded by the source corpus.
BACKGROUND Most recurrences in women with breast cancer receiving 5 years of adjuvant tamoxifen occur after 5 years. The MA.17 trial, which was designed to determine whether extended adjuvant therapy with the aromatase inhibitor letrozole after tamoxifen reduces the risk of such late recurrences, was stopped early after an interim analysis showed that letrozole improved disease-free survival. This report presents updated findings from the trial. METHODS Postmenopausal women completing 5 years of tamoxifen treatment were randomly assigned to a planned 5 years of letrozole (n = 2593) or placebo (n = 2594). The primary endpoint was disease-free survival (DFS); secondary endpoints included distant disease-free survival, overall survival, incidence of contralateral tumors, and toxic effects. Survival was examined using Kaplan-Meier analysis and log-rank tests. Planned subgroup analyses included those by axillary lymph node status. All statistical tests were two-sided. RESULTS After a median follow-up of 30 months (range = 1.5-61.4 months), women in the letrozole arm had statistically significantly better DFS and distant DFS than women in the placebo arm (DFS: hazard ratio [HR] for recurrence or contralateral breast cancer = 0.58, 95% confidence interval [CI] = 0.45 to 0.76; P < .001; distant DFS: HR = 0.60, 95% CI = 0.43 to 0.84; P = .002). Overall survival was the same in both arms (HR for death from any cause = 0.82, 95% CI = 0.57 to 1.19; P = .3). However, among lymph node-positive patients, overall survival was statistically significantly improved with letrozole (HR = 0.61, 95% CI = 0.38 to 0.98; P = .04). The incidence of contralateral breast cancer was lower in women receiving letrozole, but the difference was not statistically significant. Women receiving letrozole experienced more hormonally related side effects than those receiving placebo, but the incidences of bone fractures and cardiovascular events were the same. CONCLUSION Letrozole after tamoxifen is well-tolerated and improves both disease-free and distant disease-free survival but not overall survival, except in node-positive patients.
Subfields: Cancer Research, Genetics, Public Health, Environmental and Occupational Health
View Paper: https://www.semanticscholar.org/paper/3738a8f8640b106c513924836d62bf08b557cf75
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Public Health, Environmental and Occupational Health
Citations in the corpus
- Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007. (2007, background): “Different patterns of expected adverse events may influence patient preference for one or other treatment strategy. endocrine therapy in postmenopausal patients Clearly the availability of third generation aromatase inhibitors (AIs) [24, 84–88] has added substantially to the available treatment choi”
- Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves (2012, methodology): “These were drawn from a subset of publications [12,27-29] that formed part of a look-back review of survival time analysis methods used in economic evaluations [13].”